Bridge Bio and Finnzymes Form PCR Venture to Sell PCR Technologies | GenomeWeb
NEW YORK (GenomeWeb News) — Finnzymes Instruments and Bridge Bioscience have created a joint venture and started a new company to sell certain PCR technologies.
Under the agreement, Bridge Bio will transfer all of the physical assets and patents in its PCR business to the new company, called BioInnovations Oy, which will be controlled by Finnzymes.
According to BridgeBio’s website, the company’s PCR portfolio includes reagents and products for electroporation, electrophoresis, and transfection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.